TPX-0131

brain-penetrant mutant ALK kinase inhibitor

oral, Ph. I/II in ALK+ pre-treated cancers

undisclosed starting point, SBDD

Molecular Cancer Therapeutics

Turning Point Therapeutics, San Diego, US

2. The Turning Point Therapeutics CNS-penetrant ALK kinase inhibitor, TPX-0131, is more potent in vitro than all 5 approved ALK inhibitors against WT-ALK and many ALK resistance mutations, including…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.